or Try an Advanced Search...

    Technical Analysis for CGTX - Cognition Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.47 -0.25% 0.00
    CGTX closed down 0.25 percent on Friday, November 1, 2024, on 47 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CGTX trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Fell Below 20 DMA Bearish -0.25%
    MACD Bearish Centerline Cross Bearish -0.25%
    Calm After Storm Range Contraction -0.25%
    NR7 Range Contraction -0.25%
    Older End-of-Day Signals for CGTX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 19 hours ago
    Possible Inside Day about 19 hours ago
    60 Minute Opening Range Breakdown about 20 hours ago
    Possible NR7 2 days ago
    Fell Below 20 DMA 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CGTX Chart by TradingView
    Basic chart:

    Profile

    Cognition Therapeutics, Inc. Description

    Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Biology Alzheimer's Disease Parkinson's Disease Disorders Dementia Psychiatric Diagnosis Aging Associated Diseases Geriatrics Lewy Body Dementia Cognitive Disorders Dry Age Related Macular Degeneration Early Stage Alzheimer's Disease

    Is CGTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
    Oct 29 Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
    Oct 23 Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
    Oct 22 Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
    Oct 9 Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...
    Oct 2 Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
    Oct 1 Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
    Sep 3 Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
    Aug 22 Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
    Aug 11 Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript
    See more CGTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.95
    52 Week Low 0.34
    Average Volume 512,085
    200-Day Moving Average 1.52
    50-Day Moving Average 0.54
    20-Day Moving Average 0.48
    10-Day Moving Average 0.53
    Average True Range 0.06
    RSI (14) 44.44
    ADX 23.92
    +DI 25.22
    -DI 21.78
    Chandelier Exit (Long, 3 ATRs) 0.47
    Chandelier Exit (Short, 3 ATRs) 0.52
    Upper Bollinger Bands 0.61
    Lower Bollinger Band 0.35
    Percent B (%b) 0.47
    BandWidth 54.99
    MACD Line 0.00
    MACD Signal Line -0.01
    MACD Histogram 0.0079
    Fundamentals Value
    Market Cap 15.13 Million
    Num Shares 32.1 Million
    EPS -0.79
    Price-to-Earnings (P/E) Ratio -0.60
    Price-to-Sales 0.00
    Price-to-Book 2.50
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.48
    Resistance 3 (R3) 0.48 0.48 0.48
    Resistance 2 (R2) 0.48 0.48 0.48 0.48
    Resistance 1 (R1) 0.47 0.47 0.47 0.47 0.48
    Pivot Point 0.47 0.47 0.47 0.47 0.47
    Support 1 (S1) 0.47 0.47 0.47 0.47 0.47
    Support 2 (S2) 0.47 0.47 0.47 0.46
    Support 3 (S3) 0.46 0.47 0.46
    Support 4 (S4) 0.46